vebeglogene autotemcel (beta-globin lentiviral vector transduced autologous HSPCs) / Lantu Biopharma - LARVOL DELTA

An Open-label Study of a Gene Therapy Product (Vebeglogene Autotemcel) in Transfusion Dependent Beta-Thalassemia (clinicaltrials.gov) - P1/2 | N=6 | Active, not recruiting | Sponsor: Lantu Biopharma | Recruiting ➔ Active, not recruiting

Enrollment closed • Beta-Thalassemia • Gene Therapies • Genetic Disorders